Emergency Stroke Unit for Acute Cerebrovascular Events ( ESU-ACE-C )

Launched by BEIJING TIANTAN HOSPITAL · Jul 22, 2024

Keywords

ClinConnect Summary

The ESU-ACE-C trial is studying how well patients with a specific type of stroke, called hyperacute ischemic stroke, do when treated in a new type of Emergency Stroke Unit compared to a standard stroke unit. The goal is to see if the new unit, which uses special imaging technology, can help patients who arrive at the hospital within 4.5 hours of their symptoms starting. This trial is currently looking for participants aged 18 and older who have clear stroke symptoms and meet other specific health criteria.

If you or a loved one are considering participating, you would need to provide informed consent and meet certain requirements, such as having a baseline stroke severity score and being eligible for a specific type of medication that helps dissolve blood clots. Participants in the trial can expect to receive care in either the standard stroke unit or the new Emergency Stroke Unit. This research is important because it aims to improve treatment options for stroke patients, ultimately leading to better outcomes and recovery.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age ≥ 18 years;
• • 2. Patients who arrive at the emergency department within 4.5 hours of symptom onset\* (\*Symptom onset is defined by the "last seen normal" principle);
• • 3. Presenting with ischemic stroke symptoms;
• • 4. Pre-stroke mRS score 0-1;
• • 5. Baseline NIHSS score ≥ 5;
• • 6. Eligible for rt-PA/TNK thrombolysis;
• • 7. Informed consent signed.
• Exclusion Criteria:
• • 1. Baseline NIHSS score \< 5;
• • 2. Unable to undergo MRI because of claustrophobia;
• • 3. Patients with cardiac pacemaker/brain pacemaker/insulin pump implantation;
• • 4. Definite contraindication for rt-PA/TNK thrombolysis;
• • 5. Patients with postictal hemiparesis (Todd's paralysis) or those with concomitant neurological/psychiatric conditions who are unable or unwilling to cooperate;
• • 6. Pregnant women, nursing mothers, or reluctance to use effective contraceptive measures during the period of trial;
• • 7. Participation in other interventional randomized clinical trials within 3 months before enrollment;
• • 8. Patients deemed unsuitable for participation in this trial by the investigator or those for whom participation in this trial may result in greater risks.